All In MedTech

Device Trial Radar · NCT02148393

Implantation Enhancement by Elective Cryopreservation of All Viable Embryos

Elective Blastocyst Vitrification for Endometrial Receptivity Enhancement in High-responder Patients Undergoing in Vitro Fertilisation/Intracytoplasmatic Sperm Injection (IVF/ICSI)

Last checked: Nov 19, 2026Latest source record: Mar 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 212 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

212

Actual

Start

May 2014

Primary completion

Feb 28, 2017

Study completion Feb 28, 2017

Sponsor

Lead sponsor
Universitair Ziekenhuis BrusselAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 28, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomised controlled open-label clinical trial to compare the clinical pregnancy rates between fresh embryo transfer and elective all-embryo vitrification with thawing and transfer in a subsequent cycle in high-responders

Conditions

  • Infertility
  • OHSS

Interventions

  • Vitrification with subsequent-cycle embryo thawing/transferProcedure

    The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®). In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.

  • Intensified luteal phase support for fresh embryo transferProcedure

    A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).

  • Pregnyl®Drug

    1500 IU

  • Utrogestan®Drug

    200 mg tid

  • Progynova®Drug

    2 mg bid

  • CryoBioSystem®Device

    CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical pregnancy ratesTime frame: 7 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Brussel

    Brussels, Lisboa, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.